65,437 trials
Alzheimer's Type Dementia
Primary: Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3 — 126.503; 97.006; 127.335; 66.081 ng/mL
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
Schizophrenia · Autism
Primary: Lurasidone Primary Pharmacokinetic Parameters — 78; 140; 300; 115 ng.h/mL
Lymphoma
Primary: Number of Progression Events in 2 Years. — 41; 1; 46; 8 Event
Atrial Fibrillation
Primary: Creatinine Clearance (Recalculated Using Entries of Age, Gender, Body Weight and Serum Creatinine Made by the Physician) — 55.2 ml/min
Immunologic Deficiency Syndromes
Primary: Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs) — 691; 749 pg/ml
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Gastric Cancer
Primary: Overall Survival Time (OS) — 9.6; 7.4 months — p=0.0169
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
Bipolar Disorder
Primary: Boyko DWM Hyperintensity Value >2 in Subjects Who Received Acute Treatment for Mania — 10; 9 participants — p=>0.05
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) of Aripriprazole — 170; 136 ng/mL
Hypoxic Ischemic Encephalopathy
Primary: Feasibility Trial- the Olympic Cool Cap Will be Applied, Can the Delivered Cap Temperature be Less Than 12 Degrees Without Changing Rectal Temperature. — 2 participants
Orthostatic Hypotension
Primary: Time to Onset of Syncope/Near Syncope While on Tilt Table — 1105.6; 1626.6 seconds — p=0.0131
Male Hypogonadism · Muscle Atrophy · Sarcopenia
Primary: 1 Repetition Maximum (1-RM) Strength Testing — 129.1; 109.4; 137.2; 118.8 kg — p=<0.001
Postoperative Nausea and Vomiting
Primary: Proportion of Patients With Complete Response — 78.2; 82.7 percentage of patients